Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis

Clinical Cancer Research

Volumn 9, Issue 3, 2003, Pages 1211-1217

  Morioka, Hideo ^a,d   Weissbach, Lawrence ^a   Vogel, Tikva ^b   Nielsen, G Petur ^a   Faircloth, Glynn T ^c   Shao, Li ^a   Hornicek, Francis J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Bio Technology General   (Israel)

^c PharmaMar USA Inc   (United States)

^d KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PLASMINOGEN; RECOMBINANT PLASMINOGEN RELATED PROTEIN B; TRABECTEDIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CHONDROSARCOMA; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; CELL DIVISION; CHONDROSARCOMA; DOXORUBICIN; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MICROCIRCULATION; MIDDLE AGED; NECROSIS; NEOPLASM TRANSPLANTATION; PLASMINOGEN; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0037341360     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ellis, L. M., Liu, W., Ahmad, S. A., Fan, F., Jung, Y. D., Shaheen, R. M., and Reinmuth, N. Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin. Oncol., 28: 94-104, 2001.
2. Fogarty, M. Learning from angiogenesis trial failures. Scientist, 16: 33, 2002.
3. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
4. Cao, R., Wu, H-L., Veitonmaki, N., Linden, P., Farnebo, J., Shi, G-Y., and Cao, Y. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc. Natl. Acad. Sci. USA, 96: 5728-5733, 1999.
5. Weissbach, L., and Treadwell, B. V. A plasminogen-related gene is expressed in cancer cells. Biochem. Biophys. Res. Commun., 186: 1108-1114, 1992.
6. McGough, R. L., Aswad, B. I., and Terek, R. M. Pathologic neovascularization in cartilage tumors. Clin. Orthop. Relat. Res., 397: 76-82, 2002.
7. Tateno, T., and Ichinose, A. Expression of plasminogen-related gene B varies among normal tissues and increases in cancer tissues. FEBS Lett., 445: 31-35, 1999.
8. Lewis, V. O., O'Reilly, M. S., Gehrmann, M., Llinas, M., Schaller, J., and Weissbach, L. Inhibition of tumor growth by plasminogen-related protein-B. Anticancer Res., 21: 2287-2292, 2001.
9. Heymach, J. V. Angiogenesis and antiangiogenic approaches to sarcomas. Curr. Opin. Oncol., 13: 261-269, 2001.
10. Chao, C., Al-Saleen, T., Brooks, J. J., Rogatko, A., Kraybill, W. G., and Eisenberg, B. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann. Surg. Oncol., 8: 260-267, 2001.
11. Delaloge, S., Yovine, A., Taamma, A., Riofrio, M., Brain, E., Misset, J. L., Marty, M., and Cvitkovic, E. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients - preliminary evidence of activity. J. Clin. Oncol., 19: 1248-1255, 2001.
12. Demetri, G. D. ET-743: the U.S. experience in sarcomas of soft tissues. Anticancer Drugs, 13: S7-S9, 2002.
13. Li, W. W., Takahashi, N., Jhanwar, S., Cordon-Cardo, C., Elisseyeff, Y., Jimeno, J., Faircloth, G., and Bertino, J. R. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin. Cancer Res., 7: 2908-2911, 2001.
14. D'Incalci, M., Erba, E., Damia, G., Galliera, E., Carrassa, L., Marchini, S., Mantovani, R., Tognon, G., Fruscio, R., Jimeno, J., and Faircloth, G. T. Unique features of the mode of action of ET-743. Oncologist, 7: 210-216, 2002.
15. Friedman, D., Hu, Z., Kolb, A., Gorfajn, B., and Scotto, K. W. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res., 62: 3377-3381, 2002.
16. Lewis, V. O., Gehrmann, M., Weissbach, L., Hyman, J. E., Rielly, A., Jones, D. G., Llinás, M., and Schaller, J. Homologous plasminogen N-terminal and plasminogen-related gene A and B peptides - characterization of cDNAs and recombinant fusion proteins. Eur. J. Biochem., 259: 618-625, 1999.
17. Shao, L., Weissbach, L., Faircloth, G. T., Chabner, B. A., and Hornicek, F. J. In vitro anti-proliferative effect on sarcoma cells by ET-743 and other marine chemotherapeutics. Proc. Am. Assoc. Cancer Res., 42: 203, 2001.
18. De Pas, T., Curigliano, G., Masci, G., Catania, C., Comandone, A., Boni, C., Tucci, A., Pagani, O., Marrocco, E., and de Braud, F. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. Ann. Oncol., 13: 161-166, 2002.
19. Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., and Jain, R. K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res., 60: 2497-2503, 2000.
20. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60: 1878-1886, 2000.
21. Furumatsu, T., Nishida, K., Kawai, A., Namba, A., Inoue, H., and Ninomiya, Y, Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth. Int. J. Cancer, 97: 313-322, 2002.
22. Hornicek, F. J., Gebhardt, M. C., Wolfe, M. W., Kharrazi, D., Takeshita, H., Parekh, S. G., Zurakowski, D., and Mankin, H. J. P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clin. Orthop. Relat. Res., 373: 11-17, 2000.
23. Picci, P., Sangiorgi, L., Rougraff, B. T., Neff, J. R., Casadei, R., and Campanacci, M. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J. Clin. Oncol., 12: 2699-2705, 1994.
24. Picci, P., Böhling, T., Bacci, G., Ferrari, S., Sangiorgi, L., Mercuri, M., Ruggieri, P., Manfrini, M., Ferraro, A., Casadei, R., Benassi, M. S., Mancini, A. F., Rosito, P., Cazzola, A., Barbieri, E., Tienghi, A., Brach del Prever, A., Comandone, A., Bacchini, P., and Bertoni, F. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J. Clin. Oncol., 15: 1553-1559, 1997.
25. Hlatky, L., Hahnfeldt, P., and Folkman, J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. (Bethesda), 94: 883-893, 2002.
26. Baker, C. H., Solorzano, C. C., and Fidler, I. J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res., 62: 1996-2003, 2002.
27. Siemann, D. W., Mercer, E., Lepler, S., and Roijiani, A. M. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer, 99: 1-6, 2002.
28. Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., Huang, Z. D., Chen, Y. N., and Brem, H. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer, 57: 920-925, 1994.
29. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., and Kerbel, R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity, J. Clin. Investig., 105: R15-R24, 2000.
30. Reimer, C. L., Agata, N., Tammam, J. G., Bamberg, M., Dickerson, W. M., Kamphaus, G. D., Rook, S. L., Milhollen, M., Fram, R., Kalluri, R., Kufe, D., and Kharbanda, S. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res., 62: 789-795, 2002.
31. Li, D., Williams, J. I., and Pietras, R. J. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene, 21: 2805-2814, 2002.
32. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M-J., Gately, S., Dhanabel, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature (London), 394: 287-291, 1998.
33. Hanna, N. N., Seetharam, S., Mauceri, H. J., Beckett, M. A., Jaskowiak, N. T., Salloum, R. M., Hari, D., Dhanabal, M., Ramchandram, R., Kalluri, R., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J., 6: 287-293, 2001.
34. Gyorffy, S., Palmer, K., Podor, T. J., Hitt, M., and Gauldie, J. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. J. Immunol., 166: 6212-6217, 2001.